Epiminder shares climb as cash reserves support epilepsy device development
EPI: $0.270 +1.89% · MC: $61M
Epiminder shares climbed nearly 6% to $0.28 by 12:31 pm after the epilepsy monitoring company reported approximately $65 million in cash and no borrowings at the end of September. The company said the funds would support its DETECT study and development of its next-generation Minder device well into 2028.
Net operating cash outflow rose to approximately $10 million from $8 million in the preceding quarter, as research and development and staff costs increased. Staff costs included bonuses for the previous financial year. Epiminder also paid approximately $4 million to its largest shareholder, Cochlear, for next-generation device research and development controlled by Epiminder management. The company plans to provide an operating update at its annual general meeting on 30 October.

Comments